CSIMarket
 


Iovance Biotherapeutics Inc   (IOVA)
Other Ticker:  
 
 

IOVA's Income from Cont. Operations Growth by Quarter and Year

Iovance Biotherapeutics Inc 's Income from Cont. Operations results by quarter and year




IOVA Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December -116.38 -105.32 -99.33 -68.40
III Quarter September -113.76 -99.62 -86.12 -58.57
II Quarter June -106.53 -99.35 -81.35 -63.02
I Quarter March -107.37 -91.61 -75.45 -69.60
FY   -444.04 -395.90 -342.25 -259.59



IOVA Income from Cont. Operations fourth quarter 2023 Y/Y Growth Comment
Iovance Biotherapeutics Inc in the fourth quarter 2023 recorded loss from continued operations of $ -116.38 millions.

According to the results reported in the fourth quarter 2023, Iovance Biotherapeutics Inc achieved the best Income from Cont. Operations growth in Biotechnology & Pharmaceuticals industry. While Iovance Biotherapeutics Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the fourth quarter 2023.




IOVA Income from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Iovance Biotherapeutics Inc 's fourth quarter 2023 Income from Cont. Operations $ -116.38 millions IOVA's Income Statement
Iovance Biotherapeutics Inc 's fourth quarter 2022 Income from Cont. Operations $ -105.32 millions Quarterly IOVA's Income Statement
New: More IOVA's historic Income from Cont. Operations Growth >>


IOVA Income from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Iovance Biotherapeutics Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IOVA's IV. Quarter Q/Q Income from Cont. Operations Comment
IV. Quarter 2023 results of -116.38 millions by Iovance Biotherapeutics Inc appear even less good considering the -113.76 millions loss from continued operations a quarter before.

Within Biotechnology & Pharmaceuticals industry Iovance Biotherapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Iovance Biotherapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IOVA's IV. Quarter Q/Q Income from Cont. Operations Comment
Recent loss from continued operations of -116.38 millions by Iovance Biotherapeutics Inc look even less good if you take a look at loss from continued operations -113.76 millions in the previous quarter.

Within Biotechnology & Pharmaceuticals industry Iovance Biotherapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Iovance Biotherapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Iovance Biotherapeutics Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -444.04 $ -432.98 $ -418.84 $ -411.66 $ -395.89
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Iovance Biotherapeutics Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -444 millions in the Dec 31 2023 period.
The situation is detiriorating as the cumulative loss from continued operations is getting bigger from $ -432.98 millions in the twelve months ending a quarter before and $ -389.904 millions for the twelve months ending in the quarter Dec 31 2022.

Iovance Biotherapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Iovance Biotherapeutics Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -444 millions in the Dec 31 2023 period.
The business is getting worse as the cumulative loss from continued operations is getting bigger from $ -432.98 millions in the twelve months ending a quarter before and $ -389.904 millions for the twelve months ending in the quarter a year ago Robert  Williams told.

Iovance Biotherapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
IOVA's Income from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for IOVA's Competitors
Income from Cont. Operations Growth for Iovance Biotherapeutics Inc 's Suppliers
Income from Cont. Operations Growth for IOVA's Customers

You may also want to know
IOVA's Annual Growth Rates IOVA's Profitability Ratios IOVA's Asset Turnover Ratio IOVA's Dividend Growth
IOVA's Roe IOVA's Valuation Ratios IOVA's Financial Strength Ratios IOVA's Dividend Payout Ratio
IOVA's Roa IOVA's Inventory Turnover Ratio IOVA's Growth Rates IOVA's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Dec 31 2023
Vertex Pharmaceuticals Inc18.31%$ 18.305 millions
Avenue Therapeutics Inc 17.75%$ 17.748 millions
Steris Plc14.29%$ 14.287 millions
Medpace Holdings Inc 14.02%$ 14.021 millions
Zoetis Inc 13.70%$ 13.696 millions
Eli Lilly And Company13.01%$ 13.005 millions
Idexx Laboratories Inc12.96%$ 12.958 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com